Document is current
Any future updates will be listed below
-
Authors
Alnaqbi, Khalid A. https://orcid.org/0000-0001-5875-4663
Al-jedai, Ahmed https://orcid.org/0000-0002-4730-9086
Farghaly, Mohamed
Omair, Mohammed A. https://orcid.org/0000-0002-9373-5473
Hamad, Anas https://orcid.org/0000-0001-8606-8521
Abutiban, Fatemah M. A. https://orcid.org/0000-0002-6725-4561
Shirawi, Ali Al
Rayes, Hanan Al https://orcid.org/0000-0002-6322-0831
Aldallal, Sarah https://orcid.org/0000-0001-7623-5402
Fahmy, Sahar
Simoens, Steven https://orcid.org/0000-0002-9512-2005
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 16 October 2024
First Online: 30 October 2024
Declarations
:
: Mohammed A. Omair has received funding from Abbvie, Amgen, Bristol-Meyers-Squibb, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Organon, Roche and Sandoz. Steven Simoens (SS) is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). He has participated in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD, and has attended advisory board meetings for Pfizer, Organon, and Amgen. SS has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma, Pfizer, and Biogen, and has delivered speaking engagements for Abbott, Amgen, Biogen, Celltrion, and Sandoz. All other co-authors declared no conflict of interest. The views expressed in this manuscript are those of the authors and not of the organizations they work for.
